Armed robbery in Revesby7h
Case Western Study: Key Protein's Role in Psoriasis
CLEVELAND—Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the activity of disease ...
Key protein that intensifies psoriasis identified
Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the ...
Armed robbery in Revesby8h
Case Western Study Links Key Protein to Psoriasis
Finding offers potential new target for treatmentPsoriasis, a painful and uncomfortable inflammatory skin condition that ...
Air pollution may protect against skin cancer, finds new study, but the health risks are far more serious
Air pollution might protect against the most dangerous type of skin cancer, melanoma, a new study finds. However, it's ...
Medscape2d
Investigative Treatments for Moderate to Severe Psoriasis Reviewed
Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...
Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment
This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne - - Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ ...
Drugmakers Show Restraint on Price Increases in New Trump Era
Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...
Healio3d
Deucravacitinib improves quality of life of patients with moderate, severe psoriasis
Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...
Alumis Strengthens Leadership Team with Key Appointments
Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies ...
centerforbiosimilars4d
Switching From Ustekinumab to Biosimilar SB17 Maintains Efficacy, Safety in Patients With Psoriasis
Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...
Medindia4d
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
(9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by ...
J&J beats quarterly sales and profit estimates on cancer drug sales
Johnson amp Johnson exceeded Wall Street expectations for fourth-quarter revenue and profit with robust sales of cancer ...